|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2005-10-5
|
|
pubmed:abstractText |
The aim of this study was to test the hypothesis that angiotensin converting enzyme inhibition or angiotensin II antagonism can counteract cardiac human vascular endothelial growth factor-A165 (phVEGF-A165) induced angiogenesis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0895-7061
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1347-52
|
|
pubmed:dateRevised |
2009-2-24
|
|
pubmed:meshHeading |
pubmed-meshheading:16202860-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:16202860-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:16202860-Animals,
pubmed-meshheading:16202860-Benzimidazoles,
pubmed-meshheading:16202860-Capillaries,
pubmed-meshheading:16202860-Coronary Vessels,
pubmed-meshheading:16202860-Enalapril,
pubmed-meshheading:16202860-Gene Therapy,
pubmed-meshheading:16202860-Luciferases,
pubmed-meshheading:16202860-Male,
pubmed-meshheading:16202860-Mice,
pubmed-meshheading:16202860-Mice, Inbred C57BL,
pubmed-meshheading:16202860-Neovascularization, Physiologic,
pubmed-meshheading:16202860-Renin-Angiotensin System,
pubmed-meshheading:16202860-Tetrazoles,
pubmed-meshheading:16202860-Vascular Endothelial Growth Factor A
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart.
|
|
pubmed:affiliation |
Department of Cardiology, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
